Selling Epitalon online in 2026: what the HHS policy allows and what your store needs
The short answer
Yes, under the interim HHS policy published October 30, 2026, a licensed prescriber can write Epitalon for a named patient and a 503A pharmacy can compound it, in subcutaneous and intramuscular, in intermittent courses forms, as a single-ingredient product, from an FDA-registered manufacturer, with testing, labeling and adverse event reporting in place. It is not FDA approved and the policy can be withdrawn. To sell it online you need a provider to write the prescription, a pharmacy that meets every condition, and a storefront that makes no claim about results.
Where does Epitalon stand in October 2026?
Epitalon spent 2023 to April 2026 on FDA's Category 2 list, which told pharmacies not to compound it. On April 15, 2026 FDA took it and eleven other peptides off that list without moving them to the permitted list, which left them in limbo. On July 23 and 24, 2026 FDA's Pharmacy Compounding Advisory Committee recommended it for the 503A bulks list. Recommended. On October 28, 2026 the HHS Secretary filed an interim enforcement discretion policy, published October 30, covering Epitalon and five others.
What "enforcement discretion" means: HHS does not intend to take action against a state-licensed pharmacy, federal facility or licensed physician compounding Epitalon while FDA writes the rule, as long as every condition below is met. It is not approval, it is not binding on HHS, and HHS has said it will revisit the policy if a safety signal or quality problem appears.
What forms of Epitalon does the policy cover?
Epitalon acetate, in subcutaneous and intramuscular, in intermittent courses forms. The policy names intermittent courses rather than continuous use, which matters for how a subscription is structured. A monthly refill that never pauses is a design the pharmacy may not fill.
What does the pharmacy have to meet?
The policy lists conditions, and a pharmacy that misses one is outside it. In plain terms:
- A patient-specific prescription. from a licensed prescriber, for a named patient. Nothing in the policy allows a pharmacy to make stock for resale.
- A 503A compounder. a state-licensed pharmacy, a federal facility or a licensed physician. 503B outsourcing facilities are not covered.
- Ingredient from an FDA-registered manufacturer. that follows current good manufacturing practice, with a certificate of analysis for identity, purity, potency and contaminants on every lot.
- One active ingredient per product. no blends, even of two peptides that are each on the list.
- The permitted form and route only. each peptide is cleared for named routes, and an oral form needs documented bioavailability.
- Labeling. every product states that it is a compounded drug product and not for resale, and any co-packaged syringe is FDA 510(k) cleared.
- Adverse event and quality reporting. serious adverse events and product quality problems go to FDA MedWatch and the relevant state board, whether or not the pharmacy thinks the product caused them.
- State law still applies. the policy is federal enforcement discretion. A state board of pharmacy or medical board can still say no.
Before you list a product, ask the pharmacy for its supplier qualification record, the certificate of analysis for the current lot and its adverse event procedure. A pharmacy that cannot produce those is not operating under the policy, whatever it says on its price list.
What does a telehealth brand need to sell Epitalon?
A prescriber. Every order is a patient-specific prescription, so every order starts with a licensed clinician reviewing an intake and deciding. A provider network covering 50 states does this without you hiring doctors. The clinician can decline, and a store built on everyone being approved is built wrong.
A 503A pharmacy that meets the conditions. Either one in the platform's network, or your own, routed through Surescripts. One active ingredient per product, in a permitted form.
A store that makes no claim. Describe the product, say it is compounded and not FDA approved, show safety information, and let the clinician decide what it is for. Outcome promises are the fastest way to a demand letter and an ad account ban.
State logic. The store refuses a visit from a state the product cannot be sold into before the patient pays, not after.
A way to turn it off. The policy is interim. If it changes, the product comes off the shelf the same day and existing subscribers are told.
On Dispense Flow that is a product, an intake, a provider and a pharmacy assignment. The step-by-step guide walks through it, and the claims article covers what the page can and cannot say.
Questions
Is Epitalon FDA approved?
No. HHS said in the policy itself that it "does not grant FDA approval or establish clinical safety and effectiveness." It is enforcement discretion: HHS does not intend to act against compounders who meet the conditions while FDA writes a rule.
Which forms of Epitalon are covered?
Subcutaneous and intramuscular, in intermittent courses. Any other route is outside the policy.
Can I sell Epitalon in a blend with another peptide?
No. The policy covers products with one active ingredient. Two peptides means two prescriptions and two products, each on the list in its own right.
Can I say what it does on my store?
Only with care. There is no FDA-approved labeling to quote, no published trial to cite, and FTC rules on substantiation apply to every claim. A page can say what the product is, what it is prescribed for by the clinician, and that it is compounded and not FDA approved. Our compliance check flags outcome promises before you publish.
Does this work in every state?
No. The policy is federal. Your prescriber has to be licensed in the patient's state and your pharmacy has to be allowed to ship there, and a state board can still restrict a peptide the federal policy permits. The store has to know which states each product may be sold into.
How long will this last?
Until FDA issues a final rule on the 503A bulks list, which counsel put at 12 to 24 months, or until HHS withdraws it on a safety signal. Build the store so a product can be switched off in a day.